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Abstract
Prospective cohort studies have found that prediagnostic circulating vitamin B6 is inversely
associated with both risk of kidney cancer and kidney cancer prognosis. We investigated
whether circulating concentrations of vitamin B6 at kidney cancer diagnosis are associated
with risk of death using a case-cohort study of 630 renal cell carcinoma (RCC) patients.
Blood was collected at the time of diagnosis, and vitamin B6 concentrations were quantified
using LC-MS/MS. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated
using Cox regression models. After adjusting for stage, age, and sex, the hazard was 3
times lower among those in the highest compared to the lowest fourth of B6 concentration
(HR4vs1 0.33, 95% CI [0.18, 0.60]). This inverse association was solely driven by death from
RCC (HR4vs1 0.22, 95% CI [0.11, 0.46]), and not death from other causes (HR4vs1 0.89,
95% CI [0.35, 2.28], p-interaction = 0.008). These results suggest that circulating vitamin B6
could provide additional prognostic information for kidney cancer patients beyond that
afforded by tumour stage.
Background
Each year more than 300,000 new cases of kidney cancer are diagnosed worldwide, leading to
approximately 130,000 deaths [1]. The prognosis is strongly dependent on stage at diagnosis,
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with around 90% of stage I patients alive five years after diagnosis, compared with only 10% of
stage IV patients [2].
Kidney cancer rates are approximately two times higher for males than females, and
increase with age. In addition to these factors, hypertension, obesity and tobacco smoking are
the main established risk factors for kidney cancer [3]. Little is known on factors influencing
the survival after diagnosis, apart from tumor stage and grade. Some studies have suggested a
favorable prognosis for obese or overweight patients, which is surprising as obesity is also asso-
ciated with an increased risk of disease onset. Whether overweight and obese individuals pres-
ent with more indolent tumors or whether they benefit from earlier detection with fortuitous
diagnosis in the course of frequent medical examinations is unclear [4–7]. We recently investi-
gated biomarkers of one-carbon metabolism and kidney cancer onset and survival in two pro-
spective epidemiological cohorts, where blood samples were collected at entry to the studies, an
average of 7 years before diagnosis [8]. We reported a strong inverse relationship between lev-
els of circulating vitamin B6 and the risk of subsequent kidney cancer, as well as the risk of
death after kidney diagnosis. Although our analysis suggested that this association was driven
by deaths caused by kidney cancer, available data did not allow for a thorough cause-specific
mortality analysis, nor could we assess the importance of concentrations measured at diagno-
sis. Data were also scarce on important prognostic factors such as stage. This observation
prompted us to investigate whether vitamin B6 concentrations at diagnosis of kidney cancer
are indicative of subsequent survival, and if they are informative beyond stage or other prog-
nostic factors.
Materials and Methods
The K2 study
Participants included patients who were above 18 years of age and diagnosed with kidney can-
cer between 2007 and 2012 in one of 6 participating centres in Czech Republic, 1 center in
Romania, and 1 center in Russia. We gave participants a standardized face-to-face short life-
style questionnaire covering socio-demographic characteristics, anthropometric measures,
medical history, family history, and tobacco and alcohol use. Clinical and pathological data
were abstracted from medical charts and pathological reports. A majority of participants
underwent nephrectomy and the tumor was histologically confirmed. Follow-up for outcome
(relapse, vital status, and cause of death where relevant) was performed every 6 to 12 months
after diagnosis, using passive follow-up methods where possible (with confirmation of vital sta-
tus through active follow-up methods in case of uncertainties), and active follow-up methods
when no linkage to databases was possible. The study protocol was approved by the institu-
tional review boards of the International Agency for Research on Cancer (reference 09–24) and
all collaborating institutions, and we obtained written informed consent from all participants.
Case-cohort sampling
The case-cohort is an efficient design that allows unbiased estimation of relative risks without
the need to ascertain covariate information for an entire cohort [9]. A case-cohort sample con-
sists of a—possibly stratified—random sample of all participants in the cohort, as well as all
participants who experienced the event of interest during follow-up, but were not randomly
selected for inclusion in the subcohort. Subsequent analyses are weighted to account for the
unequal probability of inclusion in the sample. In the present study, the “cohort” was the entire
sample of renal cell carcinoma (RCC) cases, and the event of interest was death from any
cause.
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Among 2330 participants with questionnaire data available and a diagnosis of RCC, we
excluded 125 participants with no plasma sample available, 1005 participants with no follow-
up data at the time of this project, 5 participants with inconsistencies in reference dates, and 7
participants with no information on stage. From the 1188 remaining, we randomly selected
500 participants at baseline (the subcohort). We also included all participants who died during
follow-up that were not randomly selected in to the subcohort (N = 93), as well as all eligible
stage IV patients (N = 37) that had survived and were not randomly selected. Hence a total of
630 participants diagnosed with kidney cancer were included in the study. Within the ran-
domly selected subcohort, the median follow-up time was 2.6 years (minimum 5 days, maxi-
mum 6.7 years).
Biosample processing and biochemical analysis
Venous blood was obtained before or at the time of the nephrectomy, prior to any treatment.
Blood was collected in vacutainers containing ethylenediaminetetraacetic acid (EDTA), and
processed as rapidly as possible (usually within two hours). Plasma samples were stored at
−80°C, except in Ceske Budejovice, Czech Republic, where samples were stored at −20°C. All
samples were transported at −80°C to IARC for long-term storage at −150°C. Samples under-
went a single thawing cycle for aliquoting of 400uL for shipment to the Bevital laboratory in
Bergen, Norway, for analysis. Vitamin B6 (measured as pyridoxal 5’-phosphate, its active
form) was quantified using liquid chromatography coupled to tandem mass spectrometry.
Details and performance of this method have been previously published [10]. Notably it has
been shown that storage conditions and duration do not lead to substantial degradation of vita-
min B6, and that technical variation between batches is acceptably small [10].
Statistical analysis
We used Cox proportional hazards models with time since diagnosis (recruitment) as the time
scale to estimate hazard ratios (HR) and 95% confidence intervals (CI) for all-cause mortality
by categories of circulating vitamin B6. Categories were defined by splitting B6 concentrations
at quartiles of its distribution within the randomly selected subcohort. HRs for cause-specific
mortality were calculated in a competing risks model using the data augmentation method of
Lunn and McNeil [11]. To account for the case-cohort design [9] we used Barlow’s method to
weight the likelihood and computed robust variance estimates, slightly adjusted to account for
the fact that we included all cases with stage IV disease (i.e., all stage IV cases received a weight
of 1). All models included stage, age at diagnosis, and sex as covariates, with the baseline hazard
stratified by country of recruitment. We additionally adjusted for body mass index (BMI, kg/
m2), smoking status (never, former, current), cigarettes per day, alcohol drinking status (never,
former, current), and alcohol intake (ml/day of ethanol). We also conducted a sensitivity analy-
sis adjusting for Fuhrman grade (with participants with missing grade excluded), and receipt of
secondary treatment.
We investigated potential effect modification by fitting interactions between log2 trans-
formed vitamin B6 concentrations and age categories, country of recruitment, sex, stage, histo-
logical type, history of diabetes, history of hypertension, smoking status, alcohol intake status,
and categories of BMI. Model based estimates of the survival function by categories of B6 con-
centration and stage were obtained from flexible parametric survival models [12], using the
same weighting for the likelihood as applied to the Cox models. Restricted cubic splines with 2
knots (placed at the 33rd and 67th percentiles of the uncensored log survival times) were used
to model the baseline cumulative hazard.
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In a secondary analysis, we used standard, unweighted Cox regression to compute HRs for
the joint outcome of relapse (local or systemic) or death, whichever occurred first, as well as a
competing risks analysis of relapse versus death. These analyses excluded stage IV cases (who
are not disease-free after diagnosis and thus cannot relapse by definition) and those who died
who had not been randomly sampled for the subcohort, as the case-cohort sample did not
include the corresponding participants from outside the subcohort who relapsed.
All p-values are two sided, and were calculated using the Wald test. Statistical analyses were
performed using Stata 12.1 for Linux (Stata Corporation, College Station, Texas, US) and R
version 3.1.0 [13].
Results
Demographic and clinical characteristics of the study sample by vital status at the end of fol-
low-up are presented in Table 1. The sample included a higher proportion of men (63%) than
women, and were predominantly recruited from the Czech Republic (52%) and Russia (43%),
with only 5% of participants recruited in Romania. Those participants who survived until the
end of follow-up had a similar age distribution to those who died during follow-up. 518 of the
630 cases (82%) were conventional RCC. 50% of deaths occurred among participants with a
stage IV tumor, and 15% of those surviving to the end of follow-up had been diagnosed with
stage IV disease. In contrast, 72% of those surviving to the end of follow-up were diagnosed
with stage I-II disease.
Hazard of death from any cause was strongly and inversely associated with circulating con-
centrations of vitamin B6 (Table 2). After adjusting for stage, age, and sex, the hazard was 3
times lower among those in the highest compared to the lowest fourth of B6 concentration
(HR4vs1 0.33, 95% CI [0.18, 0.60]). A competing risks analysis suggested that this inverse asso-
ciation was solely driven by death from RCC (HR4vs1 0.22, 95% CI [0.11, 0.46]), and not death
from other causes (HR4vs1 0.89, 95% CI [0.35, 2.28], p-interaction = 0.008). Further adjustment
for BMI, smoking status, cigarettes per day, alcohol drinking status, and mL of alcohol per day
did not affect the estimates (Table 2). Considering relapse or death as a joint outcome, or as
separate outcomes in a competing risks analysis, yielded essentially identical estimates to the
analysis of all-cause mortality (see S1 Table), as did models that were additionally adjusted for
grade (see S2 Table), or receipt of any secondary treatment (see S3 Table).
Fig 1 presents HRs for a doubling in B6 concentration separately by categories of several
potential effect modifiers. The estimated magnitude of the association was consistent by age,
sex, stage, histology, history of diabetes and hypertension, smoking status, and alcohol intake
status. There was some indication that the association might be stronger among those with
BMI 30, but there was no statistical evidence of interaction (HR 0.48, 95% CI [0.31, 0.74] for
BMI 30 versus 0.73 (0.53 to 1.02) for BMI< 25; p-interaction = 0.28). While BMI itself was
inversely associated with hazard of death (HR for BMI 30 versus< 25 0.53, 95% CI [0.34,
0.83]), this association was attenuated somewhat by adjustment for stage (HR 0.68, 95% CI
[0.43, 1.10]), and further attenuated after additionally adjusting for both stage and categories of
circulating B6 (HR 0.76, 95% CI [0.46, 1.26]).
Model based survival functions given diagnosis at age 60 years by category of B6 concentra-
tions and stage are plotted in Fig 2. For any given stage, survival is discernibly poorer with
lower circulating B6. For instance, given a stage I diagnosis at age 60 years, we estimate the
5-year survival probability to be 0.95 [95% CI 0.92, 0.97] for the highest category of concentra-
tion, versus 0.87 (0.79 to 0.92) for the lowest. Similarly, given a stage IV diagnosis the 5-year
survival probability is 0.52 (0.31 to 0.69) for the highest category, and 0.15 (0.07 to 0.26) for the
lowest.
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Table 1. Demographic and clinical characteristics of the participants by vital status at the end of follow-up.
Vital status
alive dead
n (%) n (%) Total
Total 427 (100) 203 (100) 630
Sex Male 266 (62) 131 (65) 397
Female 161 (38) 72 (35) 233
Age at recruitment (years) [26.7,55) 118 (28) 37 (18) 155
[55,65) 161 (38) 88 (43) 249
[65,75) 115 (27) 52 (26) 167
[75,86.8] 33 (8) 26 (13) 59
Country Czech Republic 230 (54) 95 (47) 325
Russia 167 (39) 105 (52) 272
Romania 30 (7) 3 (1) 33
BMI (kg/m2) [17.2,25) 97 (23) 71 (35) 168
[25,30) 184 (43) 82 (40) 266
[30,58.5] 143 (33) 50 (25) 193
missing 3 (1) 0 (0) 3
smoking Never smoker 213 (50) 92 (45) 305
Former smoker 108 (25) 54 (27) 162
Current smoker 106 (25) 57 (28) 163
Alcohol Never drinker 266 (62) 118 (58) 384
Former drinker 38 (9) 33 (16) 71
Current drinker 123 (29) 51 (25) 174
missing 0 (0) 1 (0) 1
Diabetic Yes 65 (15) 39 (19) 104
No 362
(100)
(85) 164 (81) 526
Hypertension Yes 233 (55) 103 (51) 336
No 193 (45) 100 (49) 293
missing 1 (0) 0 (0) 1
Stage I 269 (63) 38 (19) 307
II 38 (9) 10 (5) 48
III 56 (13) 54 (27) 110
IV 63 (15) 101 (50) 164
missing 1 (0) 0 (0) 1
Grade 1 73 (17) 7 (3) 80
2 173 (41) 53 (26) 226
3 67 (16) 50 (25) 117
4 15 (4) 18 (9) 33
missing 99 (23) 75 (37) 174
Histology Conventional RCC 357 (84) 161 (79) 518
Papillary RCC 41 (10) 10 (5) 51
Chromophobe RCC 11 (3) 5 (2) 16
Other 14 (3) 4 (2) 18
Unknown 4 (1) 23 (11) 27
Received secondary treatment No 357 (84) 123 (61) 480
Yes 70 (16) 80 (39) 150
(Continued)
Circulating Vitamin B6 and Kidney Cancer Prognosis
PLOS ONE | DOI:10.1371/journal.pone.0140677 October 27, 2015 5 / 12
Discussion
We investigated whether differences in circulating concentrations of vitamin B6 at the time of
diagnosis of RCC were associated with all-cause, cause-specific, and relapse-free survival. We
observed that higher concentrations of vitamin B6 were associated with a substantially lower
risk of death, in particular RCC specific death. Notably, we estimated 5-year survival to be 52%
for stage IV cases in the highest B6 category, and 15% in the lowest.
This investigation was motivated by our recent studies of pre-diagnostic biomarkers of one-
carbon metabolism and risk of RCC in prospective cohorts [8]. In both the European Prospec-
tive Investigation into Cancer and Nutrition (EPIC) and Melbourne Collaborative Cohort
Study (MCCS) cohorts there was evidence of a strong inverse association between circulating
concentration of vitamin B6 and risk of RCC. Additionally, pre-diagnostic circulating vitamin
B6 was inversely associated with hazard of death among RCC cases in both the EPIC and
Table 1. (Continued)
Vital status
alive dead
n (%) n (%) Total
Circulating B6 (nmol/L) 1 [2.6,19.8) 83 (19) 100 (49) 183
2 [19.8,32.7) 115 (27) 52 (26) 167
3 [32.7,49.4) 110 (26) 30 (15) 140
4 [49.4,467.5] 119 (28) 21 (10) 140
doi:10.1371/journal.pone.0140677.t001
Table 2. Hazard ratios (HR) [95% confidence intervals (CI)] for risk of all cause and cause specific mortality by categories of circulating vitamin B6
concentration.
minimally adjusted† adjusted‡
Cause of death B6 group# Ndeaths HR [95% CI] p* phet§ HR [95% CI] p* phet§
all cause 1 100 1.00 .000014 1.00 .000057
2 52 0.74 [0.46, 1.18] 0.75 [0.46, 1.23]
3 30 0.47 [0.27, 0.80] 0.47 [0.27, 0.84]
4 21 0.33 [0.18, 0.60] 0.34 [0.18, 0.63]
RCC 1 86 1.00 .0078 1.00 .016
2 40 0.70 [0.42, 1.15] 0.70 [0.42, 1.18]
3 15 0.29 [0.15, 0.55] 0.30 [0.15, 0.58]
4 11 0.22 [0.11, 0.46] 0.24 [0.11, 0.50]
non-RCC 1 14 1.00 1.00
2 12 1.02 [0.44, 2.39] 1.06 [0.45, 2.50]
3 15 1.41 [0.61, 3.25] 1.40 [0.59, 3.31]
4 10 0.89 [0.35, 2.28] 0.85 [0.31, 2.31]
#Groups were deﬁned as follows: 1 [2.6, 19.8), 2 [19.8, 32.7], 3 [32.7, 49.4), 4 [49.4, 467.5] nmol/L
†Stratiﬁed by country, and adjusted for stage, age at recruitment, and sex
‡Additionally adjusted for BMI (kg/m2), smoking status, cigarettes per day, alcohol drinking status, and ethanol intake per day (mL)
*p-values for the all-cause models are from tests against the null hypothesis that the vitamin B6 coefﬁcients are identically 0 (test with 3 degrees of
freedom).
§phet-values for the competing risks model are from tests against the null hypothesis of no heterogeneity of the coefﬁcients by cause of death (RCC versus
non-RCC, test with 3 degrees of freedom).
doi:10.1371/journal.pone.0140677.t002
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Fig 1. Hazard ratios (HR) and 95% confidence intervals (CI) for a doubling in vitamin B6 concentration by potential effect modifiers. Estimates
derived from Cox models stratified by country of recruitment, and adjusted for stage, age at recruitment, and sex. p-values are fromWald tests of the
interaction terms. A separate estimate for Romania is not provided due to an insufficient number of observations.
doi:10.1371/journal.pone.0140677.g001
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MCCS cohorts. In EPIC, the HR for the highest versus the lowest fourth of concentration was
0.57 (95% CI [0.37, 0.87]). Although there was limited information available on cause of death
and disease stage, the association was slightly stronger among those known to have died from
kidney cancer, and was attenuated somewhat when adjusting for stage. Our results are consis-
tent with these initial findings, and provide further evidence that a real association exists
between vitamin B6 concentration at diagnosis and subsequent survival from RCC. Notably,
our results also demonstrate that the association is likely to be much stronger for B6 concentra-
tions at diagnosis than it is for prediagnostic concentrations. Additionally, our results suggest
that this association is restricted to death from RCC specifically rather than death from any
other cause, and is not wholly accounted for by differences in stage.
Little is known regarding factors influencing survival after RCC diagnosis. Although obesity
is a strong risk factor for RCC, with each 5 kg/m2 increment in BMI associated with an increase
in risk of approximately 30% [14], several studies have suggested that obesity might be associ-
ated with better prognosis. For instance, Choi et al. meta-analysed data from 15 prospective
studies and found that obese patients had improved overall survival [4]. Ohno et al. also found
Fig 2. Model based survival function by categories of circulating vitamin B6 and stage. Estimates derived from flexible parametric survival models
assuming proportional hazards for B6 categories, no interaction between stage and B6 categories, and a diagnosis age of 60y.
doi:10.1371/journal.pone.0140677.g002
Circulating Vitamin B6 and Kidney Cancer Prognosis
PLOS ONE | DOI:10.1371/journal.pone.0140677 October 27, 2015 8 / 12
an inverse association, and reported that the association persisted among males after adjust-
ment for stage [6]. In contrast, among 2119 RCC patients at Memorial Sloan Kettering Cancer
Center, the observed association between BMI and cause-specific mortality (HR for obese ver-
sus normal BMI 0.59, 95% CI [0.42, 0.83]) was attenuated after adjustment for stage and grade
(HR 0.75, 95% CI [0.53, 1.07]) [7]. Our data corroborate this result, suggesting that any associa-
tion between BMI and risk of death is not independent of stage.
In addition to stage attenuating the association between BMI and risk of death, we observed
further attenuation after adjustment for circulating vitamin B6. This raises the intriguing possi-
bility that the observed association with BMI is due to BMI acting as a crude marker of nutri-
tional status. Indeed, composite indices of nutritional status or deficiency have been shown to
associate with RCC prognosis. An index incorporating low BMI, low albumin, and high pre-
operative weight loss was associated with almost 3-fold higher rate of cause-specific mortality
among 369 patients with RCC at the Vanderbilt University Medical Center [15]. Similarly, an
index of nutritional deficiency including low BMI, low albumin, and low cholesterol has been
associated with approximately 2-fold higher rate of RCC-specific death [16]. Our observation
that the association with BMI is almost entirely attenuated after adjustment for vitamin B6,
and the indication that the association between vitamin B6 and survival might be strongest for
those with high BMI, lend further and direct support to the hypothesis that nutritional status
may be an important prognostic factor for RCC.
It is notable that the distribution of vitamin B6 concentrations in our sample is low com-
pared to the general population. In healthy participants from Norway who had vitamin B6
assayed using non-fasting blood samples and the same platform employed for the present
study, the median concentration was 48 nmol/L [17]. In contrast, we observed a median of 33
nmol/L in the subcohort of our study. A concentration of 30 nmol/L has been suggested as a
lower bound for normal concentration [18], and concentrations less than 20 nmol/L have been
considered deficient [19]. By these criteria, over 50% of our sample have concentrations below
the normal range, and 30% would be considered deficient. While it is tempting to infer that die-
tary intervention or supplementation might lead to improved prognosis, this inference is some-
what premature, as vitamin B6 is associated with numerous pathways implicated in cancer
development and progression, including the tryptophan metabolism pathway which is
involved in immune function and inflammatory processes [20–22]. Similarly, vitamin B6 con-
centrations are correlated with albumin [23], which has also been shown to be inversely associ-
ated with risk of RCC specific death [7, 16, 24–26]. Thus our results should not be taken as
evidence of a direct causal association between vitamin B6 concentration and prognosis.
One limitation of our study is that grade was unavailable for a substantial proportion (28%)
of participants. Nevertheless, sensitivity analyses adjusting for grade and excluding those with
missing data yielded substantively identical results, suggesting that the association between
vitamin B6 and risk of death is not explained by grade. Another limitation is that we were
unable to assess whether vitamin B6 is associated with prognosis independently of albumin,
and thus cannot attempt to disentangle whether vitamin B6 per-se confers a survival advan-
tage. It is also possible that these results may not generalise beyond Central and Eastern Euro-
pean populations, but the remarkable consistency with results observed in Western European
cohort studies using pre-diagnostic blood samples would suggest that that our results will gen-
eralise well, at least to a broader population of European origin.
In summary, aside from tumour stage, little is known about factors associated with kidney
cancer prognosis. We provide strong evidence that low circulating concentrations of vitamin
B6 at diagnosis are associated with an increased risk of death from kidney cancer, and that cir-
culating vitamin B6 provides additional prognostic information for kidney cancer patients
beyond that afforded by tumour stage. In summary, higher circulating concentrations of
Circulating Vitamin B6 and Kidney Cancer Prognosis
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vitamin B6 at the time of RCC diagnosis are strongly associated with better survival, indepen-
dently of disease stage.
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